Wegovy is not a pill. It is an injectable medication that comes as a prefilled pen you use once a week. The injection goes just under the skin in your abdomen, thigh, or upper arm. However, the same active ingredient in Wegovy (semaglutide) does exist in pill form under a different brand name, and a higher-dose oral version is in late-stage development for weight loss.
How Wegovy Is Taken
Wegovy comes as a clear, colorless liquid inside a prefilled, disposable pen. You don’t need to mix anything or attach a needle separately. Each pen is single-use: you inject it once, then throw it away. The needle is small, and most people inject themselves at home without assistance.
You take Wegovy once per week, on the same day each week, at any time of day, with or without food. The dose starts low and gradually increases over about four months to let your body adjust and reduce side effects like nausea. The schedule looks like this:
- Weeks 1 through 4: 0.25 mg
- Weeks 5 through 8: 0.5 mg
- Weeks 9 through 12: 1 mg
- Weeks 13 through 16: 1.7 mg
- Week 17 onward: 1.7 mg or 2.4 mg (maintenance dose)
If you have trouble tolerating a dose increase, your prescriber can delay the next step up by four weeks rather than pushing through the side effects.
Storage and Handling
Wegovy pens need to be kept in the refrigerator between 36°F and 46°F. If needed, you can leave a pen at room temperature (up to 86°F) for a maximum of 28 days before using it. After 28 days outside the fridge, the pen should be thrown away even if it still has medication in it. The pens should never be frozen, exposed to direct light, or left in a hot car.
Oral Semaglutide That Already Exists
The active ingredient in Wegovy is semaglutide, and there is already an oral semaglutide tablet on the market called Rybelsus. The catch: Rybelsus is FDA-approved primarily for type 2 diabetes, not weight loss. It comes in doses up to 14 mg taken daily, and its weight loss effects are modest compared to Wegovy. In studies, people taking 14 mg of oral semaglutide lost about 5.7% of their body weight over a year, while people on the 2.4 mg weekly Wegovy injection lost around 15% over the same timeframe.
The reason for that gap is absorption. Semaglutide is a protein-based molecule, and your stomach would normally break it down before it could reach the bloodstream. Rybelsus tablets contain a special absorption enhancer that creates a protective buffer around the medication in your stomach, neutralizing acid in the immediate area and helping semaglutide pass through the stomach lining intact. Even with this technology, only a small fraction of the oral dose makes it into the bloodstream, which is why Rybelsus requires a much higher milligram dose (14 mg daily) than Wegovy (2.4 mg weekly) while still delivering less of the drug overall.
Rybelsus also comes with specific instructions: you take it on an empty stomach with no more than 4 ounces of plain water, then wait at least 30 minutes before eating, drinking, or taking other medications. This ensures the absorption enhancer works properly.
A Higher-Dose Oral Version for Weight Loss
Novo Nordisk, the company that makes both Wegovy and Rybelsus, has been testing a much higher oral semaglutide dose (50 mg daily) specifically for weight loss. In the OASIS 1 trial published in The Lancet, participants taking the 50 mg oral tablet lost an average of 15.1% of their body weight over 68 weeks, compared to 2.4% with a placebo. That result is essentially equivalent to what injectable Wegovy achieves at its maintenance dose.
The trial also found that 85% of participants on the oral 50 mg dose lost at least 5% of their body weight, 69% lost at least 10%, and about one in three lost 20% or more. Those numbers represent a major jump from the currently available 14 mg oral tablet. The Drugs.com comparison page for Wegovy does list an oral tablet form alongside the subcutaneous injection, suggesting regulatory submissions for an oral Wegovy formulation are underway or have progressed, though the injectable version remains the established form most people will encounter.
Why the Injection Works Better (For Now)
The fundamental challenge with oral semaglutide is bioavailability. When you swallow a protein drug, digestive enzymes attack it and very little survives to enter your bloodstream. The absorption enhancer in semaglutide tablets helps, but it can’t fully overcome the problem. That means you need to swallow a much larger amount of the drug to get the same blood levels you’d achieve from a small weekly injection.
For people who strongly prefer a pill over a needle, the 14 mg Rybelsus is already an option, though it’s approved for diabetes rather than weight management and produces significantly less weight loss. If the 50 mg oral dose receives FDA approval for obesity, it would be the first pill to match injectable Wegovy’s results, giving people a genuine choice between the two formats.
Until then, if your goal is weight management with semaglutide, Wegovy in its current form means a once-weekly injection. Many people who were nervous about self-injecting find the prefilled pen straightforward after the first use, since the device handles most of the process automatically.